27/02/2012

A study with the participation of Vall d'Hebron Research Institute (VHIR) and the Center of Multiple sclerosis of Catalonia (CEM-Cat) together with 85 more centers of Spain determines that the therapy with Natalizumab is effective in the treatment of the multiple sclerosis. The study has evaluated the safety and the efficiency of this injectable treatment for patients with multiple sclerosis and it has been published recently in the prestigious magazine Journal of Neurology.Natalizumab has proved its effectivity in the treatment of people with multiple sclerosis in the context of clinical assays certain clinical. Nevertheless, the patients for which the treatment has been finally indicated in the clinical practice have a profile different from those who were included in the clinical assays. The aim of this study is, therefore, to gather information on the use of the Natalizumab in the clinical daily practice in Spain. The 86 centers participants around Spain, with the lead of VHIR and CEM-Cat, have presented information on characteristics of the disease at its initial stages and after receiving the treatment with Natalizumab.